Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in pulmonary embolism swept away in favor of mechanical thrombectomy. A deluge of favorable comments by experts and analysts followed the presentation during a late-breaking session at Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation, which showed more than 50% improvement in treatment effect from Penumbra’s computer-assisted vacuum thrombectomy system plus anticoagulation compared to anticoagulation alone within two days with no increase in major adverse events.